Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Safety of prohemostatic interventions.

Levi M.

Semin Thromb Hemost. 2012 Apr;38(3):292-8. doi: 10.1055/s-0032-1302444. Epub 2012 Feb 18. Review.

PMID:
22510862
2.

Reversal of novel oral anticoagulants in patients with major bleeding.

Siegal DM, Cuker A.

J Thromb Thrombolysis. 2013 Apr;35(3):391-8. doi: 10.1007/s11239-013-0885-0. Review.

PMID:
23389753
3.

Prohemostatic interventions in obstetric hemorrhage.

Bonnet MP, Basso O.

Semin Thromb Hemost. 2012 Apr;38(3):259-64. doi: 10.1055/s-0032-1302441. Epub 2012 Feb 18. Review.

PMID:
22510859
4.

Prohemostatic interventions in trauma: resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions.

Howard BM, Daley AT, Cohen MJ.

Semin Thromb Hemost. 2012 Apr;38(3):250-8. doi: 10.1055/s-0032-1306435. Epub 2012 Mar 30. Review.

PMID:
22467527
5.

Management of surgical hemostasis: systemic agents.

Levy JH, Tanaka KA.

Vascular. 2008 Mar-Apr;16 Suppl 1:S14-21. Review. Erratum in: Vascular. 2009 May-Jun;17(3):181.

PMID:
18544301
6.

Should antifibrinolytics be given in all patients with trauma?

Levi M.

Curr Opin Anaesthesiol. 2012 Jun;25(3):385-8. doi: 10.1097/ACO.0b013e3283532b29. Review.

PMID:
22459985
7.

Anticoagulants. Old and new.

Levi M, Eerenberg ES, Kampuisen PW.

Hamostaseologie. 2011 Nov;31(4):229-35. doi: 10.5482/ha-1153. Epub 2011 Jun 20. Review.

PMID:
21687916
8.

Monitoring prohemostatic treatment in bleeding patients.

Ranucci M, Baryshnikova E, Colella D.

Semin Thromb Hemost. 2012 Apr;38(3):282-91. doi: 10.1055/s-0032-1302443. Epub 2012 Feb 18. Review.

PMID:
22510861
9.

[Hemostasis and blood coagulation revisited: mechanisms and therapeutic implications].

Hermans C, Deneys V.

J Pharm Belg. 2004;59(1):15-26. Review. French.

PMID:
15129576
10.

Absorbable hemostatic agents.

Gabay M.

Am J Health Syst Pharm. 2006 Jul 1;63(13):1244-53. Review.

PMID:
16790576
11.

Prohemostatic agents to prevent perioperative blood loss.

Levy JH, Tanaka KA.

Semin Thromb Hemost. 2008 Jul;34(5):439-44. doi: 10.1055/s-0028-1092873. Epub 2008 Oct 27. Review.

PMID:
18956283
12.

Management of bleeding disorders by prohemostatic therapy.

Levi MM, Vink R, de Jonge E.

Int J Hematol. 2002 Aug;76 Suppl 2:139-44. Review.

PMID:
12430914
13.

Prohemostatic interventions in liver surgery.

Stellingwerff M, Brandsma A, Lisman T, Porte RJ.

Semin Thromb Hemost. 2012 Apr;38(3):244-9. doi: 10.1055/s-0032-1302440. Epub 2012 Feb 17. Review.

PMID:
22510858
14.

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.

Crowther MA, Warkentin TE.

J Thromb Haemost. 2009 Jul;7 Suppl 1:107-10. doi: 10.1111/j.1538-7836.2009.03429.x. Review.

15.

Prohemostatic Interventions: what's New? Preface.

Levi M.

Semin Thromb Hemost. 2012 Apr;38(3):235-6. doi: 10.1055/s-0032-1309288. Epub 2012 Apr 17. No abstract available.

PMID:
22510856
16.

The safety of fondaparinux for the prevention and treatment of venous thromboembolism.

Turpie AG.

Expert Opin Drug Saf. 2005 Jul;4(4):707-21. Review.

PMID:
16011449
17.

Safety of recombinant activated factor VII in randomized clinical trials.

Levi M, Levy JH, Andersen HF, Truloff D.

N Engl J Med. 2010 Nov 4;363(19):1791-800. doi: 10.1056/NEJMoa1006221. Erratum in: N Engl J Med. 2011 Nov 17;365(20):1944.

18.

Safety of recombinant activated factor VII in randomized clinical trials.

Arellano-Rodrigo E.

N Engl J Med. 2011 Feb 10;364(6):574-5; author reply 575-6. doi: 10.1056/NEJMc1013591#SA2. No abstract available.

PMID:
21306249
19.

Antithrombotic drugs: part I.

Gallus AS, Hirsh J.

Drugs. 1976;12(1):41-68. Review.

PMID:
789043

Supplemental Content

Support Center